About the Poster
PlatformQ Health is excited to virtually present, “The Impact of Online, Interactive Education for Enhancing the Treatment of Non-Small Cell Lung Cancer with Immunotherapy,” a one-page impact overview.
Researcher, Wendy Turell, DrPH, Vice President of CME Outcomes and Analytics at PlatformQ Health Education sought to evaluate and address knowledge and competence gaps when using immunotherapies as treatment for patients with advanced Non-Small Lung Cancer (NSLCL). These knowledge and competence gaps stem from rapid changes in research surrounding newly approved options and established guidelines. As a result, clinicians who specialize in lung cancer require education on how to optimize selection and sequencing of immunotherapies, interpret biomarker testing data, and manage treatment-related toxicities in their patients.
To bridge these gaps, the PlatformQ Health team in collaboration with the Albert Einstein College of Medicine created a live, virtual education program called, “Recent Advances in Non-Small Cell Lung Cancer with Immunotherapy: Optimizing Treatment Sequencing and Managing Toxicity” that launched on OMedLive in January 2019 and remained on-demand through July 2019.
Watch the virtual presentation of this one-page impact report, presented by Wendy Turell, DrPH, of PlatformQ Health Education to learn more about the results of this educational program.
Program Engagement Highlights
- 512 total learners with 73% being physicians, NPs, and PAs
- Nearly 100 total CME credits were issued
- 150 responses to in-session polling
- 94 total slide downloads
“I have a better understanding of immune-based therapies and now can explain them better to my patients.”
The approach to evaluating the behavioral impact of the program included an immediate pre and post-test, along with a 2-month follow-up survey. The results of these surveys showed improvement for the 4 knowledge questions and 1 competence-based question.
Behavioral Impact of the Education
- 75% of learners reported having better recognition of the immune medicated toxicities
- 67% of learners reported improved dialogue on treatment options with patients
- An estimated 4.8k patients are impacted per week by this educational program
“I am now able to understand side effects and toxicities of immunotherapy-based treatment and how to direct those patients.”
Digital Education Bridging the Gaps
This initiative proved successful in supporting oncology team members managing NSCLC patients on immunotherapies. Additionally, self-reported practice change examples showed improvements in patient/provider communication, clinical practice, and confidence in applying immunotherapy management strategies.
Want your own copy of this one-pager, or have a question? Email us at firstname.lastname@example.org.